IGF1-IGF1R signaling in tumor-associated macrophages regulates extracellular matrix organization in BRAF inhibitor-targeted melanoma.
Melanoma, particularly driven by activating mutations in the BRAF gene, has witnessed significant therapeutic advances through targeted therapies such as BRAF and MEK inhibitors. However, the development of acquired resistance remains a major clinical challenge, limiting long-term treatment efficacy. The tumor microenv...